

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Shen L, Guo J, Zhang Q, *et al.* Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. *J Immunother Cancer* 2020;8:e000437. doi: 10.1136/jitc-2019-000437

Since the online publication of this article, the authors have noticed that the author name Zuobai Wang was incorrectly spelt as Zoubai Wang. This has been corrected.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2020;8:e000437corr1. doi:10.1136/jitc-2019-000437corr1

